These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 26151607

  • 21. Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression.
    Saliba F, Fischer L, de Simone P, Bernhardt P, Bader G, Fung J.
    Ann Transplant; 2018 Oct 26; 23():751-757. PubMed ID: 30361470
    [Abstract] [Full Text] [Related]

  • 22. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M, Higashiyama H, Fukasawa Y, Itoh Y, Tamaki T.
    Nephrology (Carlton); 2015 Jul 26; 20 Suppl 2():58-60. PubMed ID: 26031588
    [Abstract] [Full Text] [Related]

  • 23. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B, Tedesco-Silva H, Ettenger R, Christian M, Bjerre A, Dello Strologo L, Marks SD, Pape L, Veldandi U, Lopez P, Cousin M, Pandey P, Meier M.
    Am J Transplant; 2021 Jan 26; 21(1):123-137. PubMed ID: 32406111
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
    Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E, Neau-Cransac M, Durand F, Houssel-Debry P, Vanlemmens C, Pageaux G, Hardwigsen J, Eyraud D, Calmus Y, Di Giambattista F, Dumortier J, Conti F.
    Am J Transplant; 2017 Jul 26; 17(7):1843-1852. PubMed ID: 28133906
    [Abstract] [Full Text] [Related]

  • 25. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Jul 26; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May 26; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 27. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar 26; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 28. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D, Silva HT, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS.
    Transplantation; 2013 Apr 15; 95(7):933-42. PubMed ID: 23422495
    [Abstract] [Full Text] [Related]

  • 29. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.
    PLoS One; 2019 Apr 15; 14(5):e0216300. PubMed ID: 31136582
    [Abstract] [Full Text] [Related]

  • 30. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D.
    Am J Transplant; 2017 Sep 15; 17(9):2363-2371. PubMed ID: 28141897
    [Abstract] [Full Text] [Related]

  • 31. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain.
    Bilbao I, Salcedo M, Gómez MA, Jimenez C, Castroagudín J, Fabregat J, Almohalla C, Herrero I, Cuervas-Mons V, Otero A, Rubín A, Miras M, Rodrigo J, Serrano T, Crespo G, De la Mata M, Bustamante J, Gonzalez-Dieguez ML, Moreno A, Narvaez I, Guilera M, EVEROLIVER study group.
    Liver Transpl; 2015 Aug 15; 21(8):1056-65. PubMed ID: 25990257
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W, Huppertz A, Rath T, Ziefle S, Rump LC, Hansen A, Budde K, Lehner LJ, Shipkova M, Baeumer D, Kroeger I, Sieder C, Klein T, Schenker P.
    Transplantation; 2017 Nov 15; 101(11):2780-2788. PubMed ID: 28658202
    [Abstract] [Full Text] [Related]

  • 33. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
    Tönshoff B, Ettenger R, Dello Strologo L, Marks SD, Pape L, Tedesco-Silva H, Bjerre A, Christian M, Meier M, Martzloff ED, Rauer B, Ng J, Lopez P.
    Am J Transplant; 2019 Mar 15; 19(3):811-822. PubMed ID: 30125462
    [Abstract] [Full Text] [Related]

  • 34. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan 15; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 35. Everolimus vs Mycophenolate Mofetil in Combination With Tacrolimus: A Propensity Score-matched Analysis in Liver Transplantation.
    De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Precisi A, Campani D, Marchetti P, Filipponi F.
    Transplant Proc; 2018 Dec 15; 50(10):3615-3620. PubMed ID: 30577246
    [Abstract] [Full Text] [Related]

  • 36. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 15; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 37. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 15; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 38. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S, TRANSFORM Investigators.
    Transplantation; 2019 Sep 15; 103(9):1953-1963. PubMed ID: 30801548
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P, Felipe C, Ferreira A, Sandes-Freitas T, Cristelli M, Aguiar W, Franco M, Campos E, Gerbase de Lima M, Tedesco-Silva H, Medina-Pestana J.
    Ther Drug Monit; 2016 Jun 15; 38(3):293-9. PubMed ID: 26919549
    [Abstract] [Full Text] [Related]

  • 40. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
    Langer RM, Hené R, Vitko S, Christiaans M, Tedesco-Silva H, Ciechanowski K, Cassuto E, Rostaing L, Vilatoba M, Machein U, Ulbricht B, Junge G, Dong G, Pascual J.
    Transpl Int; 2012 May 15; 25(5):592-602. PubMed ID: 22471345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.